1. Home
  2. NTWK vs IGC Comparison

NTWK vs IGC Comparison

Compare NTWK & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NetSol Technologies Inc.

NTWK

NetSol Technologies Inc.

HOLD

Current Price

$3.12

Market Cap

35.5M

Sector

Technology

ML Signal

HOLD

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.33

Market Cap

33.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTWK
IGC
Founded
1997
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
33.8M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
NTWK
IGC
Price
$3.12
$0.33
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.13
AVG Volume (30 Days)
48.6K
496.5K
Earning Date
11-12-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$66,501,654.00
$1,106,000.00
Revenue This Year
N/A
$3.54
Revenue Next Year
N/A
$15.12
P/E Ratio
$72.45
N/A
Revenue Growth
7.70
N/A
52 Week Low
$2.14
$0.25
52 Week High
$5.75
$0.50

Technical Indicators

Market Signals
Indicator
NTWK
IGC
Relative Strength Index (RSI) 47.03 47.12
Support Level $2.88 $0.28
Resistance Level $3.05 $0.36
Average True Range (ATR) 0.11 0.02
MACD 0.07 0.01
Stochastic Oscillator 84.62 56.90

Price Performance

Historical Comparison
NTWK
IGC

About NTWK NetSol Technologies Inc.

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: